




RealRate

PHARMACEUTICAL 2021

Adamis Pharmaceuticals Corp
Rank 365 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

**RealRate**

PHARMACEUTICAL 2021

Adamis Pharmaceuticals Corp Rank 365 of 409



The relative strengths and weaknesses of Adamis Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamis Pharmaceuticals Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 191% points. The greatest weakness of Adamis Pharmaceuticals Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 470% points.

The company's Economic Capital Ratio, given in the ranking table, is -686%, being 332% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	12,524
Cost of Goods Sold	14,894
Intangible Assets	7,158
Liabilities, Current	19,926
Liabilities, Non-Current	891
Other Assets	1,599
Other Compr. Net Income	0
Other Expenses	12,553
Other Liabilities	6,553
Other Net Income	-389
Property and Equipment	9,587
Research and Development	8,281
Revenues	16,527
Selling, General and Administrative Expense	30,581

Output Variable	Value in 1000 USD
Assets	30,867
Liabilities	27,370
Expenses	66,308
Stockholders Equity	3,498
Net Income	-50,170
Comprehensive Net Income	-50,170
Economic Capital Ratio	-686%

**RealRate**• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai